Toshiharu Morikawa
Papers
3
Total Citations
12
H-Index
2
About
Toshiharu Morikawa is a pioneering urologic surgeon whose research centers on optimizing outcomes in robot-assisted radical prostatectomy (RARP) and exploring novel chemopreventive strategies for prostate cancer. His work has made significant contributions to surgical quality improvement and non-invasive cancer management. In a landmark 2024 study, Morikawa employed the cumulative sum method to analyze the learning curve for multiple surgeons performing RARP, providing critical insights into training benchmarks and procedural standardization—a study that has already garnered 6 citations for its practical implications. Demonstrating translational vision, his 2025 investigation into luteolin, a dietary flavonoid, offered preliminary evidence of safety and clinical efficacy for prostate cancer patients under active surveillance, addressing the urgent need for effective, low-toxicity interventions. Morikawa also developed a novel predictive tool, the postoperative bladder neck to pubic symphysis ratio, to identify patients at risk for de novo overactive bladder following RARP, including Retzius-sparing approaches. With a research portfolio that bridges surgical technique, predictive modeling, and nutraceutical therapy, Morikawa is shaping the future of prostate cancer care through precision and innovation.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3